EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Real-world effectiveness and safety of lebrikizumab in adults with moderate-to-severe atopic dermatitis: a retrospective observational study with focus on head and neck involvement

Edoardo Mortato, Claudia Paganini, Marina Talamonti, Virginia Maffei, Alfredo Belcastro, Cosimo Di Raimondo, Lorenzo Tofani, Luca Bianchi, Marco Galluzzo

Dermatology Reports · 30.07.2026

DOI: 10.4081/dr.2026.10460 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Dermatology Reports, online erschienen am 30.07.2026. Verfasst von Edoardo Mortato und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Systems Medicine, University of Rome "Tor Vergata". Die Arbeit nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Lebrikizumab, an anti-interleukin (IL)-13 monoclonal antibody, is a promising treatment for moderate-to-severe atopic dermatitis (AD). We conducted a single-center, retrospective study in 21 adults with moderate-to-severe AD who were biologic-naïve and had failed or were intolerant to conventional systemic therapies. Patients received lebrikizumab 500 mg at weeks 0 and 2, then 250 mg every 2 weeks; those achieving complete remission at week 16 transitioned to monthly dosing. Assessments at baseline, weeks 6, 16, and 24 showed significant improvement in Eczema Area and Severity Index (EASI), pruritus and sleep Numeric Rating Scale (NRS), and Dermatology Life Quality Index (DLQI) scores (all p

Schlagwörter

Stichwörter der Autor:innen

Atopic dermatitisanti IL-13lebrikizumab

Autor:innen und Institutionen

  • Department of Systems Medicine, University of Rome "Tor Vergata".
  • Dermatology Unit, Fondazione Policlinico "Tor Vergata", Rome.
  • Department of Systems Medicine, University of Rome "Tor Vergata"; Dermatology Unit, Fondazione Policlinico "Tor Vergata", Rome.

Zitieren

APA

Mortato, E., Paganini, C., Talamonti, M., Maffei, V., Belcastro, A., Di Raimondo, C., Tofani, L., Bianchi, L., & Galluzzo, M. (2026). Real-world effectiveness and safety of lebrikizumab in adults with moderate-to-severe atopic dermatitis: a retrospective observational study with focus on head and neck involvement. Dermatology Reports. https://doi.org/10.4081/dr.2026.10460

Vancouver

Mortato E, Paganini C, Talamonti M, Maffei V, Belcastro A, Di Raimondo C, et al. Real-world effectiveness and safety of lebrikizumab in adults with moderate-to-severe atopic dermatitis: a retrospective observational study with focus on head and neck involvement. Dermatology Reports. 2026. doi:10.4081/dr.2026.10460

BibTeX
@article{Mortato2026,
  author = {Mortato, Edoardo and Paganini, Claudia and Talamonti, Marina and Maffei, Virginia and Belcastro, Alfredo and Di Raimondo, Cosimo and Tofani, Lorenzo and Bianchi, Luca and Galluzzo, Marco},
  title = {Real-world effectiveness and safety of lebrikizumab in adults with moderate-to-severe atopic dermatitis: a retrospective observational study with focus on head and neck involvement},
  journal = {Dermatology Reports},
  year = {2026},
  doi = {10.4081/dr.2026.10460}
}
Kostenlos starten →